PUBLISHER: IMARC | PRODUCT CODE: 1541219
PUBLISHER: IMARC | PRODUCT CODE: 1541219
The global immunoglobulin market size reached US$ 15.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.9 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.
Also known as antibodies, immunoglobulins refer to a class of glycoprotein molecules produced by plasma or white blood cells (WBCs). They are generally present in the serum and cells of the immune system and function as antibodies by explicitly recognizing and binding antigens, such as bacteria or viruses, and aiding in their destruction. Their tests help doctors diagnose immunodeficiencies, allergies, and autoimmune conditions like juvenile idiopathic arthritis, lupus, and celiac disease. At present, different classes of immunoglobulins are available around the world depending on biological features, structure, target specificity, and distribution.
Due to rapid urbanization and hectic schedules, there is a rise in the consumption of fast food among individuals. This, along with sedentary lifestyles and the increasing number of patients with medical conditions like multiple myeloma, Waldenstrom macroglobulinemia, and autoimmune disorders, represents one of the primary factors impelling the growth of the market. Additionally, rising awareness about early diagnosis and the increasing preferences for personalized medicines are contributing to market growth. Moreover, immunoglobulins through a variety of routes of administration help the body fight various infectious diseases. As a result, with the rising number of hospitalized patients with coronavirus disease (COVID-19) and an urgent need for effective therapies to prevent the spread of the pandemic, hyperimmune globulin is utilized as an effective medicine in managing the infection. Apart from this, several pharmaceutical companies are introducing new and advanced immunoglobulins with improved efficiency for the treatment of neurological disorders. Other factors, such as increasing funding for research and development (R&D) projects and the improving healthcare infrastructure are anticipated to propel the market growth further in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global immunoglobulin market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, application and mode of delivery.
IgG
IgA
IgM
IgE
IgD
Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunodeficiency Disease
Myasthenia Gravis
Others
Intravenous Mode of Delivery
Subcutaneous Mode of Delivery
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being ADMA Biologics Inc., Baxter international Inc., Biotest AG, CSL Limited, Grifols S.A, Kedrion S.p.A, LFB SA, Octapharma AG, Sanquin Plasma Products B.V. and Takeda Pharmaceutical Company Limited.